# TARSUS PHARMACEUTICALS, INC. (TARS) · Edgar & Edgarette company card

> Tarsus Pharmaceuticals (TARS) grew revenue 147% in FY2025 to $451 million, operating margin -15.7%, in line with the -15.8% median for biological products, (no diagnostic substances), equity 61.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1819790 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TARS) · [JSON](https://www.pops4.com/boards/company/TARS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $451M |
| Revenue growth, 1 year | 146.7% |
| Revenue growth per year | 67.7% |
| Operating margin | -15.7% (prior year -65.9%) |
| Net margin | -14.7% |
| Operating cash flow | −$12M |
| Capital spending | $10M |
| Free cash flow | −$22M |
| Cash | $184M |
| Long-term debt | $72M |
| Total assets | $562M |
| Total equity | $343M |
| Equity ÷ assets | 61.1% |
| Return on equity | -19.3% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: 2.84 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -15.7% in FY2025; revenue is hard to predict: its 80% range is ±73%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $451.4M (FY2025), total debt $72.4M. Experience: revenue up 146.7% on the year, up 67.7% a year over 4 years; operating margin -15.7%, up from -65.9%. Soundness: equity 61.1% of assets, return on equity -19.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $449.8M and $2.9B next year (method v4.1: its own 3-year record of growth weighed at 40% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $281.4M to $4.7B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -15.7% against a -15.8% median; growth 146.7% against 21.4%.

Range logged 2026-09-24, receipt 04209aa4687c3421, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-07-13 ([filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000048/0001819790-26-000048-index.htm))

## Recent filings

- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/0001819790-26-000076-index.htm)
- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000074/0001819790-26-000074-index.htm)
- 8-K · filed 2026-09-10 · 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000066/0001819790-26-000066-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000064/0001819790-26-000064-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/0001819790-26-000063-index.htm)
- 8-K · filed 2026-08-06 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000062/0001819790-26-000062-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001819790.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1819790

## Cite

POPS4, Edgar & Edgarette: TARSUS PHARMACEUTICALS, INC. (TARS) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/TARS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.